Click here to download the Derm Update 2006 Program in Acrobat PDF format.
Thursday, October 26, 2006
9:30 – 11:00
|
Redefining Treatment Expectations in Moderate-to-Severe Psoriasis
Dermatologists participating in this symposium will:
- Discuss practical management issues with biologic agents in the treatment of psoriatic disease based on extensive US experience,
- Recognize the key safety issues with TNF antagonists currently available in Canada,
- Obtain pearls on how to incorporate biologics into their own practice through an interactive panel discussion |
Dr. Kim Papp, Chair
Dr. Brian Feagan
Dr. Kristian Reich
Dr. Kam Shojania
Dr. Norman Wasel |
| 9:30 - 9:35 |
Welcome |
Dr. Kim Papp, Chair |
| 9:35 - 10:00 |
The Use of TNF Blockers in Chronic Inflammatory Disease: What are the
Important Safety Issues? |
Dr. Brian Feagan |
| 10:00 - 10:15 |
Changing Paradigms in Moderate-to-Severe Psoriasis |
Dr. Norman Wasel |
| 10:15 - 10:40 |
Unmet Needs of Psoriasis and the Promise of Biologics |
Dr. Kristian Reich |
| 10:40 - 10:55 |
Remicade Infusion Network:
Experience in the Rheumatology Community |
Dr. Kam Shojania |
| 10:55 - 11:00 |
Closing Remarks |
Dr. Kim Papp, Chair |
| 2:00 – 3:30 |
From Trial to Clinic: A Year of Raptiva Experience in Canada
Room: Macdonald ABCD, Fairmont Chateau Whistler Resort
Session Objectives:
Following this workshop, the attendee will be able to:
- Define the appropriate patients for biological agents
- Apply practical considerations in the use of biologics for the treatment of psoriasis, with a focus on Raptiva
- Review the efficacy and safety of Raptiva as observed in Canadian clinical practice
|
|
| |
Intro |
Dr. Charles Lynde |
| |
Raptiva: Suitable for a Wide Range of Psoriasis Patients |
Dr. Richard Langley |
| |
Clinical Cases With Raptiva (Canadian Perspective) |
Dr. Norm Wasel |
| |
Expert Panel Discussion |
Dr. Kim Papp |
| |
Close |
Dr. Charles Lynde |
| 4:00 – 5:45 |
Plenary Session 1
Room: Macdonald ABCD, Fairmont Chateau Whistler Resort |
Dr. Richard Thomas, Chair |
| 4:00 - 4:05 |
Opening Remarks |
Dr. Richard Thomas |
| 4:05 - 4:25 |
Update on Topical Therapies of Psoriasis |
Dr. John Koo |
| 4:25 - 4:45 |
Efalizumab for Patients with Palmoplantar Psoriasis |
Dr. Richard Langley |
| 4:45 - 5:05 |
Adalimumab in Psoriasis: CHAMPION Phase III Trial Results |
Dr. Richard Langley |
| 5:05 - 5:25 |
Cosmeceuticals - the Latest Novel Human Skin Pigmentation Therapy |
Dr. Lawrence F. Eichenfield,
Dr. Neil Shear |
| 5:25 - 5:45 |
Panel and Questions |
|
|
|
|
Friday, October 27, 2006 – Salle de Bal Centre & Est
9:30 – 11:00
|
New Advances in Photobiology and Photoprotection
Room: Frontenac C, Fairmont Chateau Whistler Resort
Session Objectives:
Dermatologists participating in this symposium will :
- have an update of the skin damages caused by UVA radiation
- recognize the importance of UVA protection and the need for sunscreens with broad spectrum UVA/UVB protection
- acquire knowledge of UVA protection evaluation with PPD ( Persistent Pigment Darkening ) method
- evaluate the efficacy of different sunscreens formulations and the benefits of the new filter Mexoryl XL
|
Dr Jason Rivers , Chair;
Dr Robert Bissonnette;
Anny Fourtanier, L'Oreal Recherche;
Dominique Moyal, L'Oreal Recherche;
Jean Louis Refregier, L'Oreal Recherche |
| |
ULTRAVIOLET RADIATION: PUBLIC HEALTH CONCERNS |
Dr. Jason Rivers |
| |
UPDATE ON UVA INDUCED SKIN PHOTODAMAGE |
Anny Fourtanier |
| |
IMPORTANCE OF UVA PROTECTION: SKIN CANCER AND BEYOND |
Dr. Robert Bissonnette |
| |
UVA PHOTOPROTECTION EVALUATION |
Dominique Moyal |
| |
NEW ADVANCES IN SUN CARE PRODUCTS: IMPROVED UVA PROTECTION WITH MEXORYL XL |
Jean Louis Refregier |
| 11:30 – 1:30 |
Biologics and Psoriatic Disease: Practical Management Issues and Clinical Update
Room: Macdonald ABCD, Fairmont Chateau Whistler Resort
Session Objectives:
Dermatologists participating in this symposium will;
- Discuss practical management issues with biologic agents in the treatment of psoriatic disease based on extensive US experience,
- Recognize the key safety issues with TNF antagonists currently available in Canada,
- Obtain pearls on how to incorporate biologics into their own practice through an interactive panel discussion |
Dr. Richard Thomas
Dr. Joseph Jorizzo
Dr. Richard Langley |
| 11:30 |
Introduction, Learning Objectives, Pre-Assessment (touchpads) |
Dr. Richard Thoomas |
| 11:40 |
Biologics - Practical Management Issues (US Experience) |
Dr. Joseph Jorizzo |
| 12:20 |
Safety Update: TNF Antagonists |
Dr. Richard Langley |
| 13:00 |
Panel Discussion |
|
| 13:25 |
Post-Assessment and Closing Remarks |
|
| 4:00 – 5:40 |
Plenary Session 2
Room: Macdonald ABCD, Fairmont Chateau Whistler Resort |
Dr. Chuck Lynde, Chair |
| 4:00 - 4:20 |
Objectives for Dermatological Toxicities of
anti-EGFR Therapies in Cancer |
Dr. Mario Lacouture |
| 4:20 - 4:40 |
New Aspects in the pathophysiology and Treatment of Psoriatic Arthritis |
Dr. Kristian Reich |
| 4:40 - 5:00 |
Pyoderma Gangrenosum and its Management |
Dr. Joseph Jorizzo |
| 5:00 - 5:20 |
Facial Pigmented Lesions: Diagnosis and Treatment |
Dr. Joël Claveau |
| 5:20 - 5:40 |
Effects of UVB and UVA on Human Skin Pigmentation and Prevention by Sunscreens |
Dr. Dominique Moyal |
| 5:40 - 6:00 |
Panel and Questions |
|
| 6:00 - 7:30 |
Cocktail Reception |
|
|
|
|
Saturday, October 28, 2006
| 7:00 - 11:30 |
Plenary Session 3
Room: Macdonald ABCD, Fairmont Chateau Whistler Resort |
Dr. Harvey Lui, Chair |
| 7:00 - 8:30 |
Buffet Breakfast |
|
| 8:30 - 9:00 |
Skin Therapy Update |
Dr. Stuart Maddin |
| 9:00 - 9:20 |
The Global Regulatory Village – Helpful or Harmful to Patients and Physicians |
Dr. Gavin Corcoran |
| 9:20 - 9:30 |
Panel and Questions |
|
| 9:30 - 9:55 |
Coffee Breaks and Poster Exhibits |
|
| 10:00 - 10:05 |
Opening Remarks |
Dr. Harvey Lui - Chair |
| 10:05 - 10:55 |
The Need for Advocacy (Interactive) |
Dr. Albert Shumacher |
| 10:55 - 11:05 |
Canadian Skin Patient Alliance: Progress Report |
Mr. Denis Morrice
|
| 11:05 - 11:15 |
Industry - Advocacy: Impact on Access to Treatment |
|
11:30 - 1:30 |
Boxed Lunch provided for participants not attending advisory board meetings |
|
| 2:00 - 3:30 |
Plenary Session 4
Room: Macdonald ABCD, Fairmont Chateau Whistler Resort
|
Dr. Jerry Tan, Chair |
| 2:00 - 2:20 |
The Management of Hair Disorders in Women: Too Much - Too Little |
Dr. Jerry Shapiro |
| 2:20 - 2:40 |
Topical Calcineurin Inhibitors - Where Do We Stand |
Dr. Alan Fleischer |
| 2:40 - 3:00 |
TBA |
Dr. Kirk Barber |
3:00 - 3:20
|
Panel and Questions |
| 3:20 - 3:45 |
Coffee Break and Poster Exhibits |
|
3:45 - 4:20
|
Plenary Session 5 |
Dr. Jan Dutz, Chair |
| 3:20 - 3:40 |
“Dead Lice Don't Lay Eggs" - A Product Development Story |
Dr. Bill Campbell |
| 3:40 - 4:00 |
The Skin as a site of initiation of systemic Autoimmune disease: new opportunities for
Treatment |
Dr. Jan Dutz |
| 4:00 - 4:15 |
Panel and Questions |
Dr. Denis Morrice |
| 4:15 - 4:25 |
Closing Comment |
Dr. Stuart Maddin |
| 4:30 - 6:30 |
Closing Reception |
|
|
|
|
Sunday, October 29, 2006 - Frontenac Ballroom, Fairmost Chateau Whistler Resort
| 8:30 - 11:00 |
Clinical Trial Workshop: Optimizing Your Research Site Room: Macdonald E, Fairmont Chateau Whistler ResortDirected by:
Lynne Bulger, Director Medical Affairs, Barrier Therapeutics
Paul Kidson, Director Medical Affairs, LEO Pharma |
|
| |
Topics: |
|
| 1 |
1. Site Selection: The CRO Perspective
Doug Keller, President, Moncoa Medical Research Inc.
Site Selection: The Industry Perspective
Todd Georgieff, Senior Manager, Clinical Operations, Abbott
Lynne Bulger, Director Medical Affairs, Barrier |
Doug Keller
Todd Georgieff |
| 2 |
Multidisciplinary Co-operation: Dermatology and Rheumatology |
Dr. Richard Thomas |
| 3 |
Keeping Up With the Times: Remote Data Capture |
Paul Kidson |
|
|
|
|
